Workflow
000590,控制权拟变更
Shang Hai Zheng Quan Bao·2025-08-09 06:40

Core Viewpoint - The announcement by Qidi Pharmaceutical indicates a significant change in its shareholding structure, with Hunan Sailuxian acquiring a substantial stake, leading to a shift in control of the company [1][2]. Group 1: Shareholding Changes - Qidi Pharmaceutical announced that Hunan Sailuxian will acquire 58.607 million shares from Qidi Technology Service Co., resulting in a decrease of Qidi Technology's holdings from 63.151 million shares to 4.544 million shares, reducing its ownership percentage from 26.37% to 1.90% [1][3]. - Following this transaction, Hunan Sailuxian will hold 24.47% of Qidi Pharmaceutical's shares, making it the largest shareholder, surpassing Qidi Technology Service [2][5]. Group 2: Financial Details - The shares were sold at an average price of 17.19 yuan per share, totaling approximately 1.007 billion yuan for the transaction [5]. - As of August 8, Qidi Pharmaceutical's market capitalization was approximately 2.85 billion yuan, with a closing price of 11.90 yuan per share [6]. Group 3: Company Background - Qidi Pharmaceutical, established in 1956, is recognized as Hunan Province's first pharmaceutical listed company and has notable brands such as "Guhan" [5].